Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data-Reference-Cited by-同舟云学术

Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data

Published:2019-08-22 Issue:10 Volume:36 Page:2783-2796
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Freeman Morganna,Betts Keith A.,Jiang Shan,Du Ella X.,Gupte-Singh Komal,Lu Yichen,Rao Sumati,Shoushtari Alexander N.

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-019-01060-y.pdf

Reference34 articles.

1. AIM At Melanoma Foundation. Melanoma stats, facts, and figures. https://www.aimatmelanoma.org/about-melanoma/melanoma-stats-facts-and-figures/ . Cited August 2018.

2. National Cancer Institute. Cancer stat facts: melanoma of the skin. https://seer.cancer.gov/statfacts/html/melan.html . Cited August 2018.

3. American Cancer Society. Key statistics for melanoma skin cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html . Cited June 2019.

4. Cancer.Net. Melanoma: statistics. https://www.cancer.net/cancer-types/melanoma/statistics . Cited August 2018.

5. Melanoma Research Foundation. Metastatic melanoma. https://www.melanoma.org/understand-melanoma/what-is-melanoma/metastatic-melanoma . Cited August 2018.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy for Melanoma: ASCO Guideline Update;Journal of Clinical Oncology;2023-10-20

2. Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma;European Journal of Dermatology;2023-04

3. Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors;Cancers;2023-02-16

4. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival;Cancer Immunology, Immunotherapy;2022-10-05

5. Adjuvante Anti‐PD‐1‐Antikörpertherapie bei Stadium‐III/IV‐Melanom: Anwendungsdaten aus der klinischen Routine und gesundheitsökonomische Aspekte;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2021-08